Literature DB >> 14606076

Effects of splenectomy in patients with cirrhosis undergoing hepatic resection for hepatocellular carcinoma.

Zhi-Xin Cao1, Xiao-Ping Chen, Zai-De Wu.   

Abstract

AIM: To study the effects of splenectomy in patients with cirrhosis undergoing hepatic resection for hepatocellular carcinoma.
METHODS: Twenty-six patients with HCC associated with cirrhosis were divided into hepatectomy with splenectomy group (splenectomy group, n=11) and hepatectomy without splenectomy group (non-splenectomy group, n=15). T lymphocyte subsets such as CD4, CD8, CD4/CD8, helper T (Th) lymphocyte cytokines such as interferon gamma (IFN-gamma), interleukin 2 (IL-2), interleukin 10 (IL-10) and white blood cell (WBC), platelet (PLT), total bilirubin (T-Bil) were measured and used as parameters to evaluate the effects of splenectomy.
RESULTS: There was no significant difference in CD4, CD8, CD4/CD8, IL2, IFN-gamma, IL10, WBC, PLT, T-Bil levels between two groups before surgery. Two months after operation, the levels of CD4 (41.2%+/-4.2% vs 34.7%+/-3.8%), CD4/CD8 (1.7+/-0.2 vs 1.0+/-0.2), IFN-gamma (102.3+/-15.9 pg/ml vs 86.5+/-14.8 pg/ml), IL-2(97.2+/-15.6 pg/ml vs 77.6+/-14.5 pg/ml) were increased and those of CD8 (25.6+/-3.9 vs 32.8%+/-4.1%), IL-10 (56.9+/-10.4 pg/ml vs 72.6+/-15.3 pg/ml) were decreased in splenectomy groups as compared with those in non-splenectomy group (P<0.05). WBC and PLT counts in the splenectomy group were 8.9+/-1.6 X 10(9) and 310+/-32 X 10(9), respectively, which were significantly higher than those in non-splenectomy group (3.7+/-1.4 X 10(9) and 104+/-41 X 10(9)) respectively on the 14th post-operative day. T-Bil concentration in the splenectomy group (24+/-7 micromol/L) was significantly lower than that in the non-splenectomy group (37+/-13 micromol/L) on the 7th post-operative day (P<0.05).
CONCLUSION: Splenectomy combined with hepatectomy for HCC associated with cirrhosis is helpful for the recovery of T-lymphocyte subsets and the maintenance of Th1/Th2 cytokine balance.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14606076

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  6 in total

1.  Appraisal of hepatic resection in the treatment of hepatocellular carcinoma with severe thrombocytopenia.

Authors:  Keishi Sugimachi; Yasuharu Ikeda; Morimasa Tomikawa; Akinobu Taketomi; Shuichi Tsukamoto; Katsumi Kawasaki; Shinji Yamamura; Daisuke Korenaga; Yoshihiko Maehara; Kenji Takenaka
Journal:  World J Surg       Date:  2008-06       Impact factor: 3.352

2.  HBV cccDNA in patients' sera as an indicator for HBV reactivation and an early signal of liver damage.

Authors:  Ying Chen; Johnny Sze; Ming-Liang He
Journal:  World J Gastroenterol       Date:  2004-01       Impact factor: 5.742

3.  Simultaneous hepatectomy and splenectomy versus hepatectomy alone for hepatocellular carcinoma complicated by hypersplenism: a meta-analysis.

Authors:  Wei Li; Shi-Qiang Shen; Shan-Min Wu; Zu-Bing Chen; Chao Hu; Rui-Chen Yan
Journal:  Onco Targets Ther       Date:  2015-08-19       Impact factor: 4.147

Review 4.  Safety of Simultaneous Hepatectomy and Splenectomy in the Treatment of Hepatocellular Carcinoma Complicated with Hypersplenism: A Meta-analysis.

Authors:  Xuefeng Liu; Zhiqiang Chen; Meng Yu; Wei Zhou; Xuting Zhi; Tao Li
Journal:  Gastroenterol Res Pract       Date:  2019-08-14       Impact factor: 2.260

5.  Association between cellular immune response and spleen weight in mice with hepatocellular carcinoma.

Authors:  Wei Jiang; Yu Li; Shuqun Zhang; Guangyao Kong; Zongfang Li
Journal:  Oncol Lett       Date:  2021-06-30       Impact factor: 2.967

6.  Coagulopathy in liver disease.

Authors:  Wojciech Blonski; Timothy Siropaides; K Rajender Reddy
Journal:  Curr Treat Options Gastroenterol       Date:  2007-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.